Research and development aid of ATS 300 million which Austria plans to grant to Hoffmann La Roche for the development of the anti-obesity drug Orlistat is not compatible with the common market within the meaning of Article 92(2) and (3). The proposed aid shall, therefore, not be paid.
Art. 1 Decision_act (EU) 1998/251
In forcesince 21 May 1997